Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Patience is a virtue but knowing the right time to apply it helps make you money. The post Patience At The Right Time Made LLY Stock A Swing Trading Winner appeared first on Investor's Business Daily.

Patience At The Right Time Made LLY Stock A Swing Trading Winner

Elon Musk's new pay-$8-for-Twitter-verification system has gone awry in a matter of days. Now, instead of just costing Twitter money, other companies are taking losses too.

Eli Lilly shares fall after fake verified account tweets 'insulin is free now'

New Twitter owner Elon Musk has come under fire for launching Twitter Blue, a program that allows any account to be verified for a monthly subscription, leading to widespread misinformation on the platform.

Eli Lilly Clarifies It's Not Offering Free Insulin After Tweet From Fake Verified Account—As Chaos Unfolds On Twitter

Teva Pharmaceutical

Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury decided on Wednesday.

Eli Lilly ordered to pay $176.5 mln to Teva in U.S. migraine drug patent trial

Boeing

Caterpillar

Deere & Company

Honeywell

Johnson & Johnson

Nucor

PepsiCo

Raytheon

Starbucks

Jim Cramer said that these 10 stocks have little competition and are making a comeback.

Jim Cramer says these 10 ‘old guard' stocks are making a comeback

AbbVie

Bristol-Myers

BioNTech SE

Moderna

Pfizer

With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting.

The 7 Best Pharma Stocks to Buy Now

Income investors have plenty of options, even in the current market.

2 Powerhouse Dividend Stocks to Invest in This Month

Apple

Amazon

Alphabet

JPMorgan Chase & Co

Microsoft

UnitedHealth Group

Visa

Jason Kritzer is the portfolio manager and vice president of Eaton Vance Management.

These Are The Top 10 Holdings Of Jason Kritzer

Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Data shared through platform interface may help healthcare providers make data-driven decisions± about care for adults treated with select Lilly insulins Offers compatibility with the Dexcom® Continuous Glucose Monitoring Systems, *,∞ the Tempo Blood Glucose Monitor (BGM) and other compatible BGMs, as well as wearable devices from Fitbit®, Garmin®, Google Fit® and the Apple Health app INDIANAPOLIS , Nov. 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will begin rollout of its first connected platform, the Tempo® Personalized Diabetes Management Platform, later this year in the U.S. The technology aims to help adults living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins. ±   The platform consists of three key components – the Tempo Smart Button®; a compatible app, TempoSmart™; and a prefilled insulin pen, Tempo Pen® – which work together to deliver personalized guidance for adults with diabetes.

Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform

OXFORD, England & INGELHEIM, Germany & RIDGEFIELD, Conn.

Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

NEW ORLEANS , Nov. 3, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

AKOUOS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akouos, Inc. - AKUS

INDIANAPOLIS , Nov. 3, 2022 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the BRUIN Phase 1/2 trial of pirtobrutinib at the American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022, in New Orleans, Louisiana, and virtually. Pirtobrutinib is an investigational, highly selective, potent, reversible inhibitor of the Bruton's tyrosine kinase (BTK).

Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting

Acumen Pharmaceuticals

Athira Pharma

Anavex Life Sciences

Biogen

BioVie Inc

Prothena

Roche Holding AG

Cassava Sciences Inc

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

Colgate-Palmolive

Kellogg

Kraft Heinz

Mondelez

Procter & Gamble

Constellation Brands

Cramer gave investors a list of stocks he believes can withstand the Federal Reserve's tightening cycle.

Jim Cramer says these 8 stocks can withstand the Fed's tightening cycle

Eli Lilly and Co (NYSE:LLY ) Q3 2022 Earnings Conference Call November 1, 2022 9:00 AM ET Company Participants Joe Fletcher - SVP, IR David Ricks - Chairman, CEO & President Anat Ashkenazi - SVP & CFO Daniel Skovronsky - Chief Scientific and Medical Officer Anne White - SVP & President, Lilly Neuroscience Ilya Yuffa - SVP & President, Lilly International Lilly Research Labs Jake Van Naarden - SVP, CEO, Loxo Oncology & President, Lilly Oncology Michael Mason - SVP & President, Lilly Diabetes Conference Call Participants Christopher Schott - JPMorgan Chase & Co. Terence Flynn - Morgan Stanley Umer Raffat - Evercore ISI Stephen Scala - Cowen and Company Seamus Fernandez - Guggenheim Securities Robyn Karnauskas - Truist Securities Kerry Holford - Berenberg Timothy Anderson - Wolfe Research Louise Chen - Cantor Fitzgerald & Co. Colin Bristow - UBS Geoff Meacham - Bank of America Merrill Lynch David Risinger - SVB Securities Chris Shibutani - Goldman Sachs Andrew Baum - Citigroup Mohit Bansal - Wells Fargo Securities Evan Seigerman - BMO Capital Markets Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2022 Earnings Conference Call. [Operator Instructions].

Eli Lilly and Co (LLY) Q3 2022 Earnings Call Transcript

Eli Lilly & Co. Inc.'s LLY, -3.40% steady transformation into a developer of both cutting-edge diabetes and obesity treatments is well underway.

Lilly's new diabetes drug doubled sales expectations. It may also be used to treat obesity

Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year.

Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View

The pharmaceutical group slashed its full-year fiscal guidance for the third quarter in a row. Investors are also looking at updates on the much-hyped drug Mounjaro.

Eli Lilly Stock Slips After Earnings Beat. Forecast Is the Issue.

Lilly (LLY) delivered earnings and revenue surprises of 0.51% and 0.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Q3 Earnings and Revenues Beat Estimates

Eli Lilly topped third-quarter expectations Thursday, but cut its 2022 outlook, citing exchange rate challenges and changes in tax law. The post Why Eli Lilly's Third-Quarter Beat Wasn't Enough To Save Its Guidance appeared first on Investor's Business Daily.

Why Eli Lilly's Third-Quarter Beat Wasn't Enough To Save Its Guidance

Eli Lilly & Co. Inc. LLY, +0.61% said its new Type 2 diabetes treatment Mounjaro brought in $187.3 million in sales in the third quarter of the year, beating the FactSet consensus of $183.0 million. It was the therapy's first full quarter on the U.S. market after receiving approval from the Food and Drug Administration in May.

Lilly's new Type 2 diabetes drug had $187 million in sales in the third quarter

Eli Lilly slashed its full-year fiscal guidance for the third quarter in a row. Investors are also looking at updates on the much-hyped drug Mounjaro.

Eli Lilly Earnings Beat but the Stock Falls as Forecast Is Cut

Eli Lilly & Co. LLY, +0.61% shares dipped 1.1% in premarket trades on Tuesday after the drug maker trimmed its 2022 earnings outlook, but posted stronger-than-expected third-quarter results. Lilly's net income rose 31% to $1.45 billion, or $1.61 a share, from $1.11 billion, or $1.22 a share, in the year-ago quarter.

Lilly beats adjusted earnings and revenue target but trims its 2022 view

Eli Lilly and Co on Tuesday forecast its annual profit and revenue below estimates, as a stronger dollar piled more pressure on the drugmaker struggling with lower insulin prices and generic competition for its cancer drug.

Eli Lilly's bleak annual forecast overshadows quarterly beat

Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and lower Alimta revenue following the entry of generics. Total worldwide volume in Q3 2022 increased 14%.

News for Eli Lilly Stock (LLY)